Header Logo

Connection

FERDINANDOS SKOULIDIS to Proto-Oncogene Proteins p21(ras)

Back to Details
This is a "connection" page, showing publications FERDINANDOS SKOULIDIS has written about Proto-Oncogene Proteins p21(ras).
FERDINANDOS SKOULIDIS
Connection Strength
2.612
Proto-Oncogene Proteins p21(ras)
  1. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2024 Nov 01; 14(11):2183-2208.
    View in: PubMed
    Score: 0.590
  2. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 06 24; 384(25):2371-2381.
    View in: PubMed
    Score: 0.466
  3. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 07; 8(7):822-835.
    View in: PubMed
    Score: 0.377
  4. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 2010 Nov 16; 18(5):499-509.
    View in: PubMed
    Score: 0.224
  5. A STING operation to expose KRAS and STK11 co-mutated lung cancers. Cancer Cell. 2022 10 10; 40(10):1073-1076.
    View in: PubMed
    Score: 0.128
  6. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022 03; 17(3):399-410.
    View in: PubMed
    Score: 0.120
  7. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Lung Cancer. 2022 04; 166:270-278.
    View in: PubMed
    Score: 0.120
  8. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer. 2020 Jan 31; 20(1):83.
    View in: PubMed
    Score: 0.106
  9. Co-occurring genomic alterations in?non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019 09; 19(9):495-509.
    View in: PubMed
    Score: 0.103
  10. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res. 2019 07 01; 79(13):3251-3267.
    View in: PubMed
    Score: 0.101
  11. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. Clin Cancer Res. 2016 Dec 01; 22(23):5851-5863.
    View in: PubMed
    Score: 0.082
  12. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. Lung Cancer. 2023 10; 184:107293.
    View in: PubMed
    Score: 0.034
  13. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol. 2023 07; 34(7):589-604.
    View in: PubMed
    Score: 0.033
  14. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol. 2023 06 20; 41(18):3311-3317.
    View in: PubMed
    Score: 0.033
  15. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023 03 04; 401(10378):733-746.
    View in: PubMed
    Score: 0.033
  16. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040.
    View in: PubMed
    Score: 0.031
  17. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol. 2022 07; 6:e2100547.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.